Note: Descriptions are shown in the official language in which they were submitted.
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
INTRANASAL DRUG DELIVERY DEVICE, SYSTEM, AND PROCESS
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority of United States
Provisional Patent
Applications No. 62/656463 filed April 12, 2018 and No. 62/774444 filed
December 3, 2018,
both of which are hereby incorporated herein by reference in their entirety.
FIELD
[0002] The present disclosure generally relates to the field of drug
delivery and intranasal
devices.
BACKGROUND
[0003] There are various devices currently available for delivering drugs
to the nasal
cavity. Examples of prior art intranasal delivery devices include: US
2016/0367774; US
2017/0072145; US 2016/0310683; US 2013/0331916; US 2015/0165139; US
2015/0080785; US 2016/0310683; US 7,799,337; US 2007/0789976; US 2013/0142868;
US
2014/0083424; US 2011/0132354; US 2002/0017294; US 2011/0088690; US 9,707,226;
US
8,001,963; US 9,480,644; US 9,550,036; US 5,331,954; US 6,112,743; US
6,180,603; US
7,296,566; US 5,224,471; and US 5,307,953.
[0004] The inventors have determined a need for improved intranasal delivery
devices.
SUMMARY
[0005] In accordance with an aspect, there is provided an intranasal drug
delivery device
having compliant or flexible, soft nib to precisely locate the dosage and
provide comfort for
user. The term drug can also be used herein to refer to other agents such as
vitamins,
fragrance, saline or non-pharmaceutical agents.
[0006] In accordance with an aspect, there is provided an intranasal drug
delivery device
having a cocking mechanism and actuator to load and release dosage.
- 1 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[0007] In accordance with an aspect, there is provided an intranasal drug
delivery device
having a non-air interface mechanically pressurized fluid reservoir to enable
dosing
independent of orientation and to load shot chamber. In some example
embodiments,
reservoir can be collapsible from external pressure, including ambient air
pressure.
[0008] In accordance with an aspect, there is provided an intranasal drug
delivery device
connectable to a facial or device recognition application to prevent
intentional or
unintentional misuse.
[0009] In accordance with an aspect, there is provided an intranasal
fluid delivery device
comprising a dispensing tip connected to a hollow needle, a shot chamber
carrying a fluid,
the shot chamber having a diaphragm at one end and a plunger at the other end,
and an
actuator connected to a push rod moveable toward the shot chamber and having a
locking
mechanism, wherein pushing the actuator releases the locking mechanism,
allowing the
push rod to push against the plunger, exerting pressure on the fluid and
forces the needle
through the diaphragm into the shot chamber such that the fluid flows out of
the needle into
the dispensing tip.
[0010] In accordance with an aspect, there is provided apparatus for
delivering fluid to a
nasal volume comprising a housing having a first end with a dispensing opening
and a
second end with an actuating opening, a dispensing tip coupled to the
dispensing opening, a
capsule within the housing between the actuating opening and the dispensing
opening, the
capsule comprising a tube pre-filled with fluid between a diaphragm and a
plunger, and, an
actuator coupled to the actuating opening, the actuator comprising a push rod
moveable into
contact with the plunger and held back by a locking mechanism, and a spring
urging the
push rod toward the plunger.
[0011] In accordance with an aspect, there is provided a method for
targeted intranasal
fluid delivery. The method comprises inserting a compliant dispensing tip into
a nasal cavity,
and ejecting a fluid from the compliant dispensing tip to deliver a laminar
liquid bolus to a
targeted region within the nasal cavity. The targeted region may be an
olfactory region of
the nasal cavity. Inserting the compliant dispensing tip into the nasal cavity
may comprises
inserting the compliant dispensing tip at least into an upper nares. Inserting
the compliant
- 2 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
dispensing tip into the nasal cavity may comprise positioning an end of the
compliant
dispensing tip proximate to the olfactory region. The compliant dispensing tip
may comprise
a cannula. Ejecting the fluid may comprise ejecting the fluid with a
controlled velocity profile
to limit shear forces on the fluid.
[0012] In various further aspects, the disclosure provides corresponding
systems and
devices, and logic structures such as machine-executable coded instruction
sets for
implementing such systems, devices, and methods.
[0013] In this respect, before explaining at least one embodiment in
detail, it is to be
understood that the embodiments are not limited in application to the details
of construction
and to the arrangements of the components set forth in the following
description or illustrated
in the drawings. Also, it is to be understood that the phraseology and
terminology employed
herein are for the purpose of description and should not be regarded as
limiting.
[0014] Many further features and combinations thereof concerning embodiments
described herein will appear to those skilled in the art following a reading
of the instant
.. disclosure.
DESCRIPTION OF THE FIGURES
[0015] Description
[0016] Figure 1 shows an example intranasal drug delivery device
according to some
embodiments.
[0017] Figure 2 shows an example intranasal drug delivery device with a lid
or cap
according to some embodiments.
[0018] Figure 3 shows an illustration of the olfactory region.
[0019] Figure 4 shows examples of intranasal drug delivery devices
according to some
embodiments.
[0020] Figure 5 shows an example ejection stroke and reload strokes of an
intranasal
drug delivery device according to some embodiments.
- 3 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[0021] Figure 6 shows an example internal view of a tip and tip mechanism
of an
intranasal drug delivery device according to some embodiments.
[0022] Figure 7 shows an example intranasal drug delivery device with a
removable
reservoir according to some embodiments.
[0023] Figure 8 shows an example intranasal drug delivery device according to
some
embodiments with the tip inserted in the nasal cavity.
[0024] Figure 9 shows an illustration of an integrated intranasal drug-
delivery platform.
[0025] Figure 10 shows an example single use intranasal drug delivery
device according
to some embodiments.
[0026] Figure 11 shows an example intranasal drug delivery device according
to some
embodiments.
[0027] Figure 12 shows an example intranasal drug delivery device
according to some
embodiments.
[0028] Figure 13 shows an example intranasal drug delivery device
according to some
.. embodiments.
[0029] Figure 14 shows an example intranasal drug delivery device
according to some
embodiments.
[0030] Figure 15 shows an example intranasal drug delivery device
according to some
embodiments.
[0031] Figure 16 shows an external view of an example intranasal drug
delivery device
according to some embodiments.
[0032] Figure 17 shows an external view of an example intranasal drug
delivery device
according to some embodiments.
- 4 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[0033] Figure 18 shows an example intranasal drug delivery device
according to some
embodiments.
[0034] Figures 19 a-c show an example intranasal drug delivery device
according to some
embodiments.
[0035] Figures 20 a-c show an example intranasal drug delivery device
according to some
embodiments.
[0036] Figure 21 shows an example intranasal drug delivery device
according to some
embodiments.
[0037] Figure 22 shows an example intranasal drug delivery device according to
some
embodiments.
[0038] Figure 23 shows an example intranasal drug delivery device according to
some
embodiments.
[0039] Figure 24 shows an example intranasal drug delivery device according to
some
embodiments.
[0040] Figure 25 shows an example intranasal drug delivery device according to
some
embodiments.
[0041] Figures 26 a-b show an example intranasal drug delivery device
according to some
embodiments.
[0042] Figures 27 a-b show an example intranasal drug delivery device
according to some
embodiments.
[0043] Figure 28 shows an example intranasal drug delivery device according to
some
embodiments.
[0044] Figures 29 a-c show an example intranasal drug delivery device
according to some
embodiments.
- 5 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[0045] Figures 30 a-c show an example intranasal drug delivery device
according to some
embodiments.
[0046] Figure 31 shows an example intranasal drug delivery device
according to some
embodiments.
[0047] Figure 32 shows an example intranasal drug delivery device according to
some
embodiments.
[0048] Figures 33 a-c show an example intranasal drug delivery device
according to some
embodiments.
[0049] Figure 34 shows an example intranasal drug delivery device with a
dispensing tip
having a bulbous end portion according to some embodiments.
[0050] Figure 35 shows an example intranasal drug delivery device with a
dispensing tip
having an alpha loop according to some embodiments.
[0051] Figure 36 shows images from a scan of a test subject during
testing of a prototype
device with a tracer fluid.
DETAILED DESCRIPTION
[0052] Embodiments of methods, systems, and apparatus are described through
reference to the drawings.
[0053] Currently disposable intranasal drug delivery devices are
characterized by low
accuracy/uniformity of drug dosing, no design for anatomic variability and
poor design for
human factors ¨ efficacy and safety. The applications where these shortcomings
are most
detrimental are: direct-to-brain delivery path (uptake through olfactory
epithelium into CSF,
action in brain), systemically acting drugs (uptake through mucosa into
vasculature, systemic
action), vaccines (uptake and action in mucosa), and topically acting drugs
(uptake and
action in mucosa).
- 6 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[0054] The following provides for intranasal delivery of new and existing
drugs, with the
following benefits: less cost, increased effectiveness, increased safety (both
to patient and
society), and increased convenience (in terms of health care).
[0055] The following provides for opportunities in terms of design for
markets where
access to health care is challenged (humanitarian impact) and in terms of
design for
prevention of drug misuse.
[0056] Figure 1 shows an example intranasal drug delivery device 100
according to some
embodiments.
[0057] The device 100 has a compliant or flexible, soft nib 102 (as
opposed to a hard nib)
to precisely locate the dosage. The soft nib 102 also provides comfort for
user and may
minimize blocking by the nasal wall or congestion.
[0058] Septal deviation can cause different health related problems. In some
embodiments compliant, soft nib 102 conforms to the anterior aspect of the
intranasal
passage. In some embodiments the soft nib 102 is biased to follow the
patient's septum.
This allows the tip 110 to be placed in a location in the nasal cavity to
discharge medicine
targeting the olfactory region and accommodates differences in nasal cavity
anatomy.
[0059] In some embodiments compliant, soft nib 102 has a kiss-cut valve
near the tip 110.
The valve reduces the partial discharge at the front and backend of the
actuation. The tip
110 also reduces or eliminates air or contaminates from contacting the line-
fill remaining in
the nozzle between dosing. In some embodiments the orientation of the kiss cut
is off set
from the end of the tip 110 for directing the medicine in the direction of the
olfactory region of
the nasal anatomy. The nib 102 can be a multiple material over-moulded nib in
some
embodiments. As shown in Figure 34, in some embodiments the nib may have a
bulbous or
ball shaped end portion 3400 to ease the insertion and facilitate better
laminar flow along the
nasal ridge. As shown in Figure 35, in some embodiments, the compliant nib
utilizes an
'alpha loop' 3500 to facilitate positioning an end of the dispensing tip past
an obstruction.
One of the tricks in interventional cardiology to pass a guidewire past a
stricture or calcified
obstruction is to force the flexible tip guide wire into the obstruction. The
tip will naturally
- 7 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
bend back on itself and the wire finds its way through the obstruction with
the alpha loop
leading. The larger bearing surface helps to steer the wire to the point of
least resistance
and it will slip through the stricture/obstruction. This embodiment may be
utilized in trauma
where a nose may be less than perfect, this could be the shape that would help
the
compliant nib find its mark.
[0060] The device 100 has an actuator 106 (e.g. button, trigger) and cocking
mechanism
108 to release dosage that is reproducible to reduce human error/variation.
Use of a cock-
and-release mechanism in some embodiments promotes steady positioning during
delivery
and reduces the need for priming of the device 100, thereby reducing the
possibility of
operator error. In some embodiments a finger press button actuation discharges
the shot
chamber. This method of actuating the device 100 requires very little
dexterity or fine motor
skills which may be of particular importance to patients whose motor skills
may be impaired
e.g. patients with Parkinson's. Priming can refer to ensuring full liquid
filling dosing/metering
mechanism suitable for pumping of the liquid including but not limited to
positive
displacement pumping.
[0061] The device 100 has an internal reservoir that can be under
pressure constantly in
some embodiments to enable dosing independent of orientation (e.g. the user
can be
standing up or laying down and it will work). The reservoir may be a bag and
may be
collapsible by external pressure, including ambient air pressure. The pressure
within the
reservoir may change depending on the spring used, but it can always be under
some
amount of pressure.
[0062] In some embodiments the device 100 has no air-port for filling,
storing or actuating
the device 100. This allows for traveling or transport by air, particularly
unpressurized
aircraft or higher elevations and may be useful for oxygen sensitive medicine
and extending
shelf life of certain medicines, particularly where there is no cold-chain
infrastructure. In
addition, this makes the device difficult to tamper with. In some embodiments,
there can be
an air bleed port.
[0063] In some embodiments the shape of the device 100 allows for correct
nozzle
positioning and ergonomic grip that does not engage the shoulder, wrist, or
any part of the
- 8 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
other arm not activating the device 100. The design of device 100 promotes
minimal use of
shoulder and arm movement.
[0064] In some embodiments the design of device 100 is made highly
ergonomic in form,
taking inspiration both from a wider remote controller design and a more
dexterous pen
design.
[0065] The ergonomics and considered human factors create a step change in the
state
of the art for nasal delivery devices. The design minimizes human error,
allowing for a
targeted, repeatable, and metered dose delivery. The design accommodates a
consumable
drug reservoir for short to long term use, while allowing for a low cost
single patient
consumable. This gives the ability for a wide variety of drugs to be filled at
the point of care
or by pharmaceutical filling lines. The design allows for, as an example, a
compliant, soft nib
102 with an ultra-soft, matte finish, elastomeric shroud.
[0066] The compliant, soft nib 102 of the device is entered into the
intranasal cavity and
uses the common internal nasal geometry to guide the tip proximate to the
olfactory region.
The compliant soft nib 102 stops at a distance from the olfactory region and
the ejected drug
bolus is guided to the olfactory by the native geometry of the nasal anatomy.
The device
mechanism supports a pocketable form being based on compact and low-cost
injection-
mouldable parts.
[0067] Figure 2 shows an example intranasal drug delivery device 100 with
a lid 202 or
cap according to some embodiments.
[0068] In some embodiments the lid 202 may be used with the cocking mechanism
108,
or instead of cocking mechanism 108, as part of reloading the intranasal drug
delivery
device 100. The addition of the lid 202 increases the grip size of the drug
delivery device
100 and prevents misfiring of the drug delivery device 100. In some
embodiments lid 202
may provide extra space for full hand grip when attached to bottom of device
100. In some
embodiments lid 202 is shaped to increase the surface area without obstruction
by hand
when in use so that machine readable indicia (i.e. URL code) can be added to
the increased
surface area.
- 9 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[0069] In some embodiments, the device 100 may include rechargeable energy
storage to
provide motive energy with separate actuation. Rechargeable energy may include
electrical,
chemical or pressurized fluid storage.
[0070]
Figure 3 shows an illustration of the nasal cavity 300 including the
olfactory region
306, upper nares 308 and lower nares 310.
[0071]
In topical drug delivery, drug is delivered to the entire mucosa, i.e. both
the upper
nares 308 and lower nares 310. In systematic drug delivery, drug is delivered
through the
mucosa of the upper nares 308 into the vasculature. In direct-to-brain drug
delivery, drug is
delivered mainly through the olfactory region 306 diffusion through the
olfactory mucosa.
.. The olfactory path may be short and drugs might be transported through the
cribriform plate
within the cerebrospinal fluid draining from olfactory bulb. This may also
involve the
participation of trigeminal nerves.
[0072]
Current drug formulations for nasal delivery use standard sprays with no
specificity
to the olfactory region 306, relatively small molecules are used, and
formulations are mainly
water-based with some alcohols. For non-active ingredients in drug
formulations for nasal
delivery a wide variety of functionality is used: solvents, mucoadhesive,
agents, absorption
enhancers, viscosity modifiers, pH buffers, antioxidants, preservatives,
surfactants and
more.
[0073] The majority of airflow passes through the lower nares 310. Therefore,
sneezing
would likely not expel liquids deposited in the olfactory region 306. Nasal
congestion may
affect mainly the lower nares 310 while the olfactory region 306 stays clear.
[0074]
Targeted direct-to-brain drug delivery may be achieved through saturation of
the
olfactory region 306 with an excipient/drug combination.
The drug may travel via
extracellular transport to the Central Nervous System, via the cribriform
plate. This targeted
delivery is intended to reduce both topical and system delivery, allowing for
safer and more
effective drug delivery.
- 10-
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[0075] In some embodiments the device 100 may be adapted by the addition of a
lateral
atomizer tip to achieve the current state of the art of topical drug delivery
by saturating the
entire mucosa, or systemic drug delivery by targeting the Upper Nares 308.
[0076] The Olfactory plateau is generally located to the posterior aspect
of the Radix line.
This correlates to the Nasal Bridge length, which is measured from the soft
tissue of the
Nasion (SeIlion) to the Subnasale.
[0077] Figure 4 shows examples of intranasal drug delivery devices
according to some
embodiments with reservoir 402 and compliant tip 404.
[0078] Figure 5 shows an example release and reload mechanism 500 according to
some
embodiments. Release and reload mechanism 500 may be incorporated into an
intranasal
drug delivery devices such as, for example, device 100.
[0079] The release and reload mechanism 500 has a reservoir 502 containing a
drug for
delivery into the nasal cavity.
[0080] The release and reload mechanism 500 has an insertion needle 504 for
insertion
into the reservoir 502.
[0081] In some embodiments reservoir 502 is a bag and may be collapsible
by external
pressure, including ambient air pressure.
[0082] In some embodiments, reservoir 502 is removable and insertion
needle 504 is
inserted through a silicon stopper in the top of reservoir 502 for drawing the
substance into
the device 100. The silicon stopper has re-sealing properties for air
sensitive medicine. The
insertion needle 504 can be left in the bottle from which the medicine for the
device was
obtained. The filling process can eliminate the need for a separate syringe.
In some
embodiments, this may be referred to as a lure lock.
[0083] The release and reload mechanism 500 has actuator 506 connected to
release
spring 508.
-11 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[0084] The release and reload mechanism 500 has plunger 510, load valves 512
and load
chambers 514.
[0085] The release and reload mechanism 500 has shot chamber 516, fluid
chamber 518,
release valves 520 and nozzle 522. The nozzle 522 may be in fluid
communication with the
nib 102 such that fluid is ejected from nozzle 522 and through nib 102 or as
described
below.
[0086] In some embodiments release valves 520 may comprise an elongated
duckbill
valve in tip to reduce and valve the line/dead volume.
[0087] In some embodiments, reservoir 502 is held under tension by
compression spring
524. A constant and predetermined fluid pressure may be maintained by
compression
spring 524 pushing up from the bottom of the reservoir towards the shot
chamber 516 and
nozzle 522 and plunger 510. This constant liquid pressure charges the load
chamber 514
without exposing the medicine to air or metal springs typical in most nasal
pumps. In some
embodiments, this may avoid the use of tubing between the reservoir 502 and
shot chamber
.. 516. This can reduce dead volume of medication or medication left in line
after use. This
can ensures dosing accuracy is not compromised by air entering the shot
chamber 516 and
no content remains in the shot chamber 516 or reservoir 502 after the last
usable medicine
was administered. The constant pressure enables dosing independent of user
orientation.
[0088] In some embodiments the compliant, soft nib 102 is designed to
discharge a
laminar flow and this may include a turbulent boundary, discreet liquid slug
ideally suited for
maximizing dose delivery to the flat narrow section of nasal cavity leading up
to the olfactory
region. Delivery of laminar liquid slug assists in capillary action required
for maximum
medicine reaching the olfactory. In some embodiments, the laminar stream is
created by
tube array or hydrodynamic focusing.
[0089] In some embodiments the design of the chamber and fluid path can
promote high
accuracy in ejected volume.
[0090] In some embodiments device 100 is cocked by pushing down, or
compressing, the
bottle. This method of preparing the device for actuating requires very little
dexterity or fine
- 12 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
motor skills. This method of preparing the device for administrating medicine
may be of
particular importance to patients whose motor skills may be impaired e.g.
patients with
Parkinson's. The device can be oriented in any direction and the reloading of
the shot
chamber and the shot performance will not be affected i.e. the device is not
gravity sensitive.
[0091] In some embodiments the compliant, soft nib 102 is extended by
cocking the
device. This reduces over length profile of the device for shipping, shelf
space and
pocketing. In the resting position the device has a less 'menacing' look.
[0092] In some embodiments cocking the device 100 may activate a dose counter.
In
some embodiments cocking may activate a separate shot counter for each dosing
session.
[0093] In some embodiments cocking may activate a dose delay. In some
embodiments
cocking may activate a timer to remind patient when to activate between shots
needed for
dosing session. The delay between shots accommodates drug dosing indications
including
the timing of maximum drug absorption via the olfactory tight junction and the
natural
clearing of the mucosa cilia.
[0094] In some embodiments cocking may change the exposed color 112 between
the
upper bottle sleeve 104 and base 108. This, along with an extended nozzle tip
(which in
some embodiments does not fit in the lid 202 while cocked) gives the patient
or care giver a
clear visual and/or feel the device is ready for dosing or storage. In some
embodiments
exposed color 112 is made with glow plastic for darkness which promotes ease
and
convenience of nighttime use and for patients sensitive to light e.g. for
administering
medicine that dilates pupils.
[0095] In some embodiments nozzle has an adjustable nostril stop 114.
This stop gives
patient feedback the nozzle has arrived at the optimum nostril depth. The stop
also reduces
sniffing/snorting during activation.
[0096] In some embodiments, the drug may be delivered by the intranasal
drug delivery
device 100 by delivery of a liquid jet, burst or plug, rather than a spray. In
some
embodiments the design of the compliant, soft nib 102, the nozzle 522, and the
valves in the
reload mechanism 500 may be designed to optimize laminar ejection of drug.
- 13-
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[0097] Technology for liquid delivery works for a wide variety of liquid
properties. This
technology may be adapted to olfactory, systemic and topical delivery of drugs
through an
intranasal drug delivery device 100.
[0098] In some embodiments intranasal drug delivery device 100 may use
particular liquid
properties (such as viscosity and surface tension) to ensure prolonged
residence of the
delivered liquid in the target area (i.e. the olfactory region) due to
capillary bridging.
[0099] In some embodiments intranasal drug delivery device 100 may
include excipients
in the liquid drug for delivery with particular characteristics. For example,
excipients may
have thixotropicity (higher viscosity at rest which improves residence time in
the olfactory
region 306, and lower viscosity at under shear which improves ease of metering
and
delivery) through additives such as cellulose. As a further example,
excipients used may
impact surface tension of a drug to promote wetting and capillary bridging in
olfactory region.
As a further example, excipients used may be pre-approved by the Federal Drug
Administration for shorter development time.
[00100] In some embodiments intranasal drug delivery device 100 may include a
measurement method or accessory to determine the ideal compliant, soft nib 102
size, or
nozzle 522 type.
[00101] In some embodiments intranasal drug delivery device 100 may include a
mechanical or electronic timer and/or lock mechanism to prevent overdosing.
Intranasal
drug delivery device 100 may incorporate use of mobile technology for
identifying users and
tracking use to prevent overdosing. Intranasal drug delivery device 100 may
incorporate use
of a cock-and-release mechanism to promote steady positioning during drug
delivery. These
additions assist with patient compliance.
[00102] In some embodiments intranasal drug delivery device 100 may be used in
one or
more of the following applications: 1) drugs directly targeting the brain via
the olfactory
region, 2) systemically acting drugs (e.g. better systemic bioavailability or
less degradation
than via the GI tract), 3) vaccines eliciting a mucosal immune response, and
4) topically-
acting drugs.
- 14 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[00103] In some embodiments the intranasal drug delivery device 100 may have
one or
more of the following features: 1) hand held, 2) useable with a single hand,
3) designed for
ambidextrous use, 4) the priming mechanism is simple and intuitive to the
user, 5) there is a
clear indication when the dose is primed, 6) the form promotes proper
positioning in the
nasal cavity, 7) designed to require a single user action to deliver a primed
dose, 8)
designed to prevent the user from dispensing partial doses, and 9) useable for
multiple
doses.
[00104] In some embodiments the intranasal drug delivery device 100 is
intended to be
filled by a pharmacist or other medical professional. In some embodiments the
intranasal
drug delivery device 100 shall contain means for preventing unintended refills
of the
reservoir 502.
[00105] In some embodiments the intranasal drug delivery device 100 is
designed for
multiple uses. In some embodiments the intranasal drug delivery device 100
uses a
disposable or a refillable reservoir 502. In some embodiments the compliant,
soft nib 102 is
disposable.
[00106] In some embodiments intranasal drug delivery device 100 is designed
with a
floating gasket in a disposable or reusable reservoir 502.
[00107] In some embodiments, the drug delivery device 100 may integrate with a
system
involving mobile technology such as, for example, face recognition and
position tracking,
Gyroscopic position tracking of device and correlation with facial position,
use of NFC to
track number of shots.
[00108] In some embodiments, the drug delivery device 100 may enable
electrically
activated drug delivery such as lontophoresis. In some embodiments, the drug
delivery
device 100 may involve applying an ionic charge to the drug molecule to
enhance transport.
In some embodiments, the drug delivery device 100 may involve an extending tip
that
telescopes.
[00109] In some embodiments, intranasal drug delivery device 100 is designed
to use a
foam as an excipient to assure residence time in target area yet allow air to
pass.
- 15-
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[00110] In some embodiments intranasal drug delivery device 100 has barbs to
lock a
gasket at the end of travel to prevent misuse by refilling.
[00111] In some embodiments intranasal drug delivery device 100 has a piston
that scores
the chamber walls as it travels to the top of the reservoir with each
actuation. This renders
the device useless after a single use.
[00112] In some embodiments intranasal drug delivery device 100 is a multi-
dose device
with a sterile barrier to avoid contamination.
[00113] Figure 6 shows an example intranasal drug delivery device 100
according to some
embodiments including fluid chamber 602, nozzle 604, compliant, soft nib 606,
actuator 608,
exposed colour 610 and base 612.
[00114] Figure 7 shows an example intranasal drug delivery device 700 708, 710
according
to some embodiments: with the base 702 connected to the intranasal drug device
700, with
the base 702 removed and the removable reservoir 704 inserted into the
intranasal drug
delivery device 708, and with the removable reservoir 704 partially removed
from intranasal
drug delivery device 710. In some embodiments, a latch mechanism 706 retains
the
removable reservoir 704 in the device.
[00115] Figure 8 shows an intranasal drug delivery device 100 inserted into
the nasal
cavity of a patient with the tip touching the olfactory region 306. In some
embodiments a
speculum may be used as an accessory to open the nostril. In some embodiments
the
device 100 may be include an accessory part to guide the tip.
[00116] The compliant, soft nib 102 of the device is entered into the
intranasal cavity and
uses the common internal nasal geometry to self-guide the compliant, soft nib
102 to the
olfactory region. The compliant, soft nib 102 is held from lateral deviation
via the flanking
medial septum, and the lateral nasal wall.
[00117] In some embodiments when the device 100 is activated, an internal
metering
chamber ejects a repeatable and metered dose into the superior/posterior
aspect of the
olfactory region. A laminar flow is produced, as opposed to conventional
atomization or
- 16 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
spray, to ensure that the ejected dose gets delivered to the target area,
rather than
spreading in the entire intranasal space. Due to the Coanda effect, the
ejected excipient
adheres to the medial, lateral and superior aspect of the olfactory corridor
while still motive.
[00118] When the motive energy of the ejected liquid has dissipated, opposing
wall
capillary motion allows the excipient to coat the entire olfactory area. This
is due to the
combination of excipient surface tension (which is caused by cohesion within
the excipient)
and mucoadhesive properties between the excipient and olfactory mucosa wall.
[00119] To achieve residence time, and as a result of capillary action, the
excipient will be
held in the olfactory corridor due to a capillary bridge effect caused by the
opposing walls of
the medial, lateral and superior aspect of the olfactory corridor. Thus
preventing the
excipient from draining to the inferior aspect of the nasal vault. An
adequately high viscosity
or thixotropic property of the excipient helps prolonging residence time.
[00120] In one embodiment the proposed method for targeted drug delivery using
the
device 100 is as follows: 1) The compliant tip is placed to the anterior
aspect of the olfactory
.. corridor; 2) The excipient is ejected out of the tip in a "reasonably"
laminar jet, and towards
the posterior aspect of the olfactory corridor; 3) Due to the Coanda effect,
jet ejection will
cause the excipient to adhere to the medial, lateral and superior aspect of
the olfactory
corridor while still motive; 4) When the motive energy of the ejected liquid
has dissipated,
opposing wall capillary motion allows the excipient to coat the entire
olfactory area. This is
due to the combination of excipient surface tension (which is caused by
cohesion within the
excipient) and mucoadhesive properties between the excipient and olfactory
mucosa wall; 5)
To achieve residence time, and as a result of capillary action, the excipient
will be held in the
olfactory corridor due to a capillary bridge effect caused by the opposing
walls of the medial,
lateral and superior aspect of the olfactory corridor. Thus preventing the
excipient from
draining to the inferior aspect of the nasal vault. An adequately high
viscosity or thixotropic
property of the excipient helps prolonging residence time.
[00121] Figure 9 illustrates an integrated intranasal drug-delivery platform
900 including an
intranasal drug delivery device 902, a mobile device 904, an intranasal device
software
- 17-
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
application 906, a core application program interface 908, and device
generated data 910
that may be shared with shareholders 912.
[00122] The device 902 can connect to a software application 906 installed on
a mobile
device 904 for data logging to flag or track misuse and compliance. For
example, the
intranasal device software application 906 can capture images up the nasal
cavity to flag
misuse, implement user biometric authentication for compliance, capture timing
data of
dosage for compliance, provide alerts or reminders to user and so on.
[00123] In some embodiments a software application will be available in
association with
the device 100 to create an integrated hardware and software intranasal drug-
delivery
platform 900. This includes a database for the storage of data generated from
device 100
that serves as a basis for extension to a permission-based personal data
ecosystem
platform.
[00124] In some embodiments the software application may be extended to become
a
platform for more broad data aggregation and permission-based sharing. A
patient's
personal data could be collected and exchanged with permission to/from all
parties who
have a role and accountability for administering (dispensed and applied)
intranasal
treatments. The data exchange portal would provide patient insight aimed at
aligning and
continuously influencing positive behavior for optimum health care delivery.
The extension
will facilitate sharing of different types of smartphone-based personal data
to different
stakeholders such as other patients, guardians, doctors, clinics, clinical
trial researches,
health care providers, patient medical insurers, doctor insurers, health care
insurers, drug
developers, pharmacies, patient peer support groups, disease/disorder
researchers,
disease/disorder NGO's, government regulators, law enforcement/first
responders. Privacy
and control of personal data are important. A user may wish to share data in
certain
circumstances, based on incentives or goodwill.
[00125] In some embodiments components of an integrated intranasal drug-
delivery
platform 900 may comprise an intranasal drug delivery device 902 that is
inextricably linked
with a specified medicine and an individual patient through device and patient
verification;
intranasal drug delivery device 902 that provides machine readable signals
(fiducial markers)
- 18-
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
at time of scrip writing, scrip filling, patient dosing, patient possession,
and device
redemption (i.e. patient life cycle events); on-going data harvesting,
transit, storage and
retrieval capability; aggregation and anonymization of personal data into
mineable and
usable data sets eg. reporting, analytics, gamification, incentivizing, etc.;
personal data for
optimizing patient's immediate and ongoing healthcare and a permission-based
sharing
system.
[00126] Categories of data that an integrated intranasal drug-delivery
platform 900 may
utilize include a patient profile; stakeholder profiles to manage data that
has been shared
with them; non-medical passive personal data (recovery of which may be
ongoing); medical /
biometric personal data (recovery of which may be ongoing); event driven
personal data at
time of scrip writing, scrip filling, patient dosing, patient possession, and
device redemption
(i.e. patient lifecycle); and event driven prompting to influence immediate
behavior.
[00127] For an example of an integrated intranasal drug-delivery platform 900
for a user
that has been prescribed a drug that is dispensed with intranasal drug
delivery device 902,
.. 1) the user receives an alert on his/her mobile device 904 signaling that
it's time to take a
scheduled dose of drug, 2) the user unlocks the mobile device 904 using native
identity
authentication (passcode, fingerprint or facial recognition) and the
intranasal device software
application 906 opens on the mobile device, 3) the user touches the mobile
device 904 to
the intranasal drug delivery device 902 or initiates another form of
recognition, 4) the user
uses the mobile device 902 for facial recognition validation, 5) the
intranasal device
software application 906 prompts the user for measuring pre-actuation
metrics/biometrics
(relevant metrics may be determined by clinician, for example, cognition
survey, HR
measurement, short video capture to determine emotional state/impairment
etc.), 6) the user
completes any inputs needed to complete pre-actuation tests, 7) the intranasal
device
software application 906 determines that the intranasal drug delivery device
902 has been
actuated (the action may be timestamped and recorded, methods for confirming
actuation
include Bluetooth connectivity, visual image, sound, colour change, artificial
intelligence that
recognizes actuation), 8) the intranasal device software application 906
prompts the user for
measurements of post-actuation biometrics (relevant metrics may be determined
by
clinicians); 9) the user is taken back to dashboard as part of an interface
controlled by
- 19-
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
software application 906 where he/she can track different metrics and manage
permissions
(who can see what data).
[00128] Figure 10 shows an example single use intranasal drug delivery device
1000,
pump 1002 incorporating a reservoir, a pump locking mechanism 1004, and
compliant, soft
nib 1008, with a nib locking mechanism 1006, shot chamber 1010 and spray tip
1012. In
some embodiments the pump 1002 would be a spring actuated piston and the pump
locking
mechanism 1004 would lock with the nib locking mechanism 1006.
[00129] In some embodiments the device can include an olfactory marker that
will be
included with the excipient/drug that will provide biofeedback to the user.
This may take the
form of olfactory active marker that can signal to the user that the
drug/excipient has been
delivered to the olfactory region. This may include, but not be limited to
markers which
provide feedback of missed, un-deployed, deployed or over deployed
drug/excipient. The
marker can be included in the drug/excipient formulation or in some
embodiments be added
during the ejection process. In some embodiments, the marker may be included
without the
active drug agent to provide feedback to the user that an application and
dosage (without the
drug agent) was successful soliciting a psychological response.
[00130] Figure 11 shows an example intranasal drug delivery device 1100
according to
some embodiments. The device 1100 comprises an outer chassis 1108 with a
dispensing
opening at a first end and an actuating opening at a second end. A dispensing
tip is coupled
to the dispensing opening, and an actuator 1130 is coupled to the actuating
opening. As
described below, fluid can be delivered to a nasal volume through the
dispensing tip by
pressing on the actuator 1130.
[00131] In some embodiments, the device 1100 is configured to receive a
carpule 1120
(which comprises a diaphragm 1110, tube 1112, shot chamber 1114, and plunger
1116 as
described below) pre-filled with a fluid, such as for example a pharmaceutical
fluid. In the
Figure 11 example, the device 1100 comprises an enclosure 1122 slidably
received within
the outer chassis 1108 and shaped to accept a carpule 1120.
- 20 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[00132] The carpule 1120 comprises a tube 1112 with an interior shot chamber
1114 that
contains a fluid. In some embodiments, shot chamber 1114 may carry medication,
such as
ketamine of other pharmaceuticals, for delivery to a patient's nasal cavity or
olfactory region.
The shot chamber 1114 has a plunger 1116 on one end, and a diaphragm 1110 on
the
opposite end from the plunger 1116. The device 1100 is configured such that
when a user
engages the actuator 1130, the fluid in the shot chamber 1114 is delivered
through the
dispensing tip with predetermined flow characteristics. In the example
illustrated in Figure
11, the dispensing tip comprises a flexible cannula or nib 102 configured to
deliver a laminar
liquid slug, as described above.
[00133] In some embodiments, plunger 1116 may be engaged by a push rod 1124.
In the
Figure 11 example, the push rod 1124 is located at the bottom of the enclosure
1112, and a
spring 1134 is compressed between the push rod 1124 and a push button 1132. A
locking
mechanism 1128 holds the push rod 1124 and prevents it from engaging with
plunger 1116
until the push button 1132 is pressed. In the illustrated example, the locking
mechanism
1128 comprise a pair of pivotable tabs with inner ends engaging the push rod
and outer
ends extending past the outer edges of the enclosure 1122 such that when the
enclosure
1122 is pushed into the chassis 1108 by pressing on the push button 1132 the
tabs pivot to
release the push rod 1124. In other embodiments, the locking mechanism may
comprise
one or more tabs of a lock material which is breakable by pressing on the push
button 1132.
[00134] The diaphragm 1110 is puncturable by the needle 1106. Needle 1106
connects to
channel 1104 in flexible nib 102, which may be inserted into the nasal cavity
for fluid delivery
as described above. When engaged, the fluid in shot chamber 1114 is forced
through
needle 1106 and channel 1104 into the nasal cavity. Arms 1126 may assist the
user in
gripping device 1100 and engaging push button 1132.
[00135] In some embodiments, to assemble device 1100, carpule 1120 may be
inserted
into the carpule enclosure 1122. The carpule enclosure 1122 may then be
inserted into
outer chassis 1108. In the illustrated example, the chassis 1108 comprises a
resilient lip
1109 and the actuator opening deforms slightly to receive the carpule
enclosure 1122 and
carpule 1120, then holds them within the chassis 1108. In other embodiments,
seals may be
added to assist in detection of tampering.
- 21 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[00136] Use of a carpule may be advantageous in certain situations because it
is a
commonly manufactured vessel for medication and may be made of a material that
is non-
reactive with medication, such as glass.
[00137] Figure 12 shows an example intranasal drug delivery device 1100
according to
some embodiments, wherein carpule 1120 is inserted in carpule enclosure 1122
and the
carpule enclosure 1122 is inserted in outer chassis 1108, but the actuator
1130 has not been
engaged by the user and locking mechanism 1128 holds push rod 1124 such that
plunger
1116 is not engaged and fluid in shot chamber 1114 is not under pressure. Arms
1126 may
be folded outward or inward against outer chassis 1108. The device 1100 may be
stored
.. without the fluid in shot chamber 1114 being under pressure. Flexible nib
102 may be
placed in the nasal cavity of the patient prior to the actuator 1130 being
engaged by the
user.
[00138] Figure 13 shows an example intranasal drug delivery device 1100
according to
some embodiments, wherein the user has engaged the push button 1132, for
example, by
pushing it with their thumb. The user may hold the device 1100 in their hand
using arms
1126 in a folded out orientation. When user pushes the push button 1132, the
locking
mechanism 1128 releases push rod 1124. In some embodiments, the locking
mechanism
may comprise one or more tabs that break off to release push rod 1124, making
the device
1100 useable only once. In other embodiments, the locking mechanism may
comprise one
or more tabs that fold or cantilever out of the way to release push rod 1124.
When the
locking mechanism 1128 is engaged it prevents the push rod 1124 from exerting
pressure
on the plunger 1116.
[00139] When the push rod 1124 presses against the plunger 1116 it puts the
fluid in shot
chamber 1114 under pressure, and will move the carpule 1120 toward the needle.
In some
.. embodiments, a spring 1134 may be included to such that the push rod 1124
exerts even
pressure on plunger 1116, and once the locking mechanism 1128 is released the
spring
1134 will cause carpule 1120 to move further into outer chassis 1108 toward
needle 1106
until needle 1106 punctures diaphragm 1110. In some embodiments a user
continues to
push on the push button 1132 to move the carpule 1120 into outer chassis 1108
until the
needle 1106 punctures diaphragm 1110.
- 22 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[00140] In some embodiments, actuator 1130 may be a push button located at the
bottom
of device 1100, in other embodiments, actuator 1132 may be located on the side
of outer
chassis 1108.
[00141] In some embodiments, device 1100 may be designed for one-time use,
with a
locking mechanism 1128 comprising tabs that break off, or other sacrificial
clips or structures
such that carpule enclosure 1122 may not be removed from outer chassis 1118 to
replace
the spent carpule 1120 with a new carpule 1120 without the device 1100 being
damaged.
[00142] Figure 14 shows an example intranasal drug delivery device 1100
according to
some embodiments, wherein the user has pushed the actuator 1130 such that it
causes the
needle 1106 to puncture diaphragm 1110 so that the tip of needle 1106 is in
contact with the
fluid in shot chamber 1114. The fluid in shot chamber 1114 is under pressure
from the
plunger 1106 and may enter needle 1106 and flow through channel 1104 in nib
102. Fluid
may flow through channel 1104 to be deposited in the nasal cavity or olfactory
region of a
patient.
.. [00143] Figure 15 shows an example intranasal drug delivery device 1100
according to
some embodiments, wherein the user has pushed the actuator 1130 such that push
rod
1124 has pushed plunger 1116 to reach diaphragm 1110, ending the ejection of
fluid.
[00144] Figure 16 shows an external view of an example intranasal drug
delivery device
1100 according to some embodiments, wherein arms 1126 are hinged with hinge
1602 and
.. may be folded against outer chassis 1108 for storage, packing and
transport. Hinge 1602
may be a living hinge comprised of thin material, for example.
[00145] Figure 17 shows an external view of an example intranasal drug
delivery device
1100 according to some embodiments, wherein arms 1126 are folded outward from
the
outer chassis 1108, providing a grip for the user when using the device 1100.
In the folded
out position arms 1126 may provide a grip for a user wearing gloves or a user
with dexterity
challenges.
- 23 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[00146] Figure 18 shows an example intranasal drug delivery device 1100
according to
some embodiments, wherein the dispensing tip comprises an atomizer 1103
designed to
deliver a spray of fluid into the nasal cavity rather than a laminar liquid
slug.
[00147] Figures 19 a-c show an example intranasal drug delivery device 1900
according to
some embodiments, wherein a two stage triggering mechanism is executed with a
single
button push.
[00148] When actuator 1902 is first pushed by a user, the carpule 1904 is
pressed into a
needle 1906. The needle 1906 pierces the diaphragm 1908 (i.e. the carpule
septum) and
opens a fluid path through the channel 1910 (cannula) as shown in Figure 19b.
Actuator
1902 is connected directly to plunger 1914. When the actuator 1902 is pressed
a second
time by a user, spring 1912 releases and depresses the plunger 1914, ejecting
fluid through
the channel 1910 as shown in Figure 19c.
[00149] Spring 1912 may be released by breaking a shear pin 1916 into pieces
1918 and
1920, as shown in Figures 19b and 19c. In other embodiments the spring 1912
may be
released when injection molded breakoff points or wings snap off of the
plunger 1914. In
other embodiments the spring 1912 may be released by a ball detent mechanism,
molded
snap fit component or other mechanism that is activated by reaching a pre-set
force. In still
other embodiments the spring 1912 may be released by the press force
separating a magnet
in the plunger from a magnet in the system body.
.. [00150] The travel of plunger 1914 is limited by a stop mechanism 1904 to
set a total dose.
Stop mechanism may comprise actuator projections 1922 that engage the base of
the
carpule 1924.
[00151] Figures 20 a-c show an example intranasal drug delivery device 1900A
according
to some embodiments, wherein a two stage triggering mechanism is executed with
a single
.. pushing motion. In this embodiment, the actuator 1902A is connected to
spring 1912A,
which is connected to plunger 1914A. After actuator 1902A is pushed by a user,
the carpule
1904A is pressed into a needle 1906A and the needle 1906A pierces the
diaphragm 1908A
and opens a fluid path through the channel 1910A (cannula) as shown in Figure
20b, a
- 24 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
further press on the actuator 1902A builds up spring force in the user's hand
(or other
method used to press the button). When sufficient spring force is achieved,
the actuator
1902A is released. The actuator 1902A may be released by several different
methods, as
described above. The spring force built up behind the actuator 1902A then
rapidly
compresses the spring 1912A between the actuator 1902A and the plunger 1914A.
The
spring 1912A then dispenses the fluid from the channel 1910A.
[00152] In some embodiments, the device comprises a dampening mechanism,
examples
of which are described further below with reference to Figures 21-33. Elements
such as the
dispensing tip, the needle that pierces the diaphragm, and an outer body are
not shown in all
views, but may be included in some embodiments. In each of these example
embodiments,
the device 2100/2200/2300/2400/2500/2600/2700/2800/2900/3000/3100/3200/3300 is
configured to eject a jet of fluid through a channel with a controlled
velocity profile. This
assists in limiting shear on the delivered drug, some of which may be damaged
by shear.
For example, in some embodiments the device is configured to eject a jet of
fluid starting at
a high initial velocity but dropping linearly to a near zero jet velocity at
the end of jet
dispensing.
[00153] Figure 21 shows an example device 2100 according to some embodiments,
wherein a plunger 2102 is pushed by a spring 2104. In the Figure 21
embodiment, the
velocity of the plunger 2102 is controlled by an eddy current brake connected
to the traveling
end of the spring 2104. In the Figure 21 embodiment, the dampening mechanism
comprises
a magnet 2106 connected to the plunger 2102 moves through a conductive jacket
2108,
generating eddy currents and limiting the maximum plunger speed. In another
embodiment
the velocity of the plunger 2102 may be controlled by having magnet 2106 spun
by a helix
on a shaft connected to the traveling end of the spring (not shown).
[00154] Figure 22 shows an example device 2200 according to some embodiments,
wherein the velocity of the plunger 2202 travel is controlled by a dampening
mechanism
inherently formed by the construction of the device 2200 and the materials
chosen. For
example, in some embodiments part tolerances and material variations are
controlled to
provide a plunger 2202 friction and spring 2204 K value configured to ensure
desired jet
velocity profile.
- 25 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[00155] Figure 23 shows an example device 2300 according to some embodiments,
wherein the velocity of the plunger 2302 is controlled by a dampening
mechanism
comprising a viscous dampener 2304 connected to the traveling end of the
spring 2306. The
dampener 2304 is filled with air or with viscous liquid (e.g. oil). The
dampener 2304 controls
the velocity of the traveling end of the spring 2306. Maximum velocity is
limited by the
dampener 2304, and as the spring 2306 extends, it's driving force decreases.
This provides
an initially high velocity followed by a decrease in velocity over the total
dispensed volume.
[00156] Figure 24 shows an example device 2400 according to some embodiments,
wherein the velocity of the plunger 2402 is controlled by a dampening
mechanism
comprising a sealed chamber 2404 attached to the back of the device 2400
connected to a
spring 2408, which is connected to the plunger 2402. Air must be drawn into
the chamber
2404 to allow the plunger 2402 to advance, but air flow into the chamber 2404
is limited by
ether 1) a flow control valve (not shown) or 2) a simple flow restriction 2406
(e.g. narrow
channel, orifice plate).
[00157] Figure 25 shows an example device 2500 according to some embodiments,
wherein the dampening mechanism comprises a spring 2502 used to compress a
body of air
(e.g. pushing on a bellows, pushing on a diaphragm, pushing a piston) into a
sealed
chamber 2504. The compressed air flow through a flow restriction 2506 that
controls air flow
rate to the device 2500. The outside of the device 2500 body seals to the
sealed chamber
2504 (e.g. 0-ring seal). The air then pushes on the back side 2508 of the
piston 2510,
pushing the drug out of the channel 2512. Because the flow rate of air is
controlled by the
flow restriction 2506, the rate of travel for the piston 2510 is controlled.
The flow restriction
2506 may be simple, like an orifice plate, narrow tube, or narrow drilled
hole, but it may also
be a pneumatic device like a pressure relief valve, or flow control valve.
[00158] Figures 26 a-b show an example device 2600 according to some
embodiments,
wherein control over the velocity of the plunger 2602 is be achieved by a
dampening
mechanism comprising a container 2604 of compressed gas (e.g. CO2 canister,
sealed
canister of air, N2, etc.). The container 2604 of compressed gas is connected
to the flow
restriction 2606 by piercing a membrane 2608 or septum or by connecting with a
valve. A
leak point may be added to the chamber to cause pressure applied to the device
2600 to
- 26 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
dissipate over time. This provides a decreasing velocity profile for the fluid
jet. The
compressed gas container may be connected to the device 2600 chamber by
piercing a
membrane on the canister, by a valve, or by a similar mechanism.
[00159] Figures 27 a-b show an example device 2700 according to some
embodiments,
wherein the dampening mechanism comprises a piston 2702, sealed chamber 2704,
pin and
ball valve 2706. In this embodiment, the piston 2702 is moved and compressed
gas in
sealed chamber 2704 is provided instantaneously using a mechanically operated
valve such
as pin and ball valve 2706. When the piston 2702 reaches the top of the
chamber 2704, a
pin 2708 is pushed by the piston 2702, opening a ball valve 2710 to release
pressure into
the shot chamber 2712.
[00160] Figure 28 shows an example device 2800 according to some embodiments,
wherein a plunger 2802 is pushed by an electric motor 2804 (e.g. stepper
motor, DC motor,
brushless motor, etc.) which provides the function of both actuating force and
a dampening
mechanism. Circuitry onboard the electric motor 2804 controls the plunger 2802
velocity to
set the desired ejected fluid velocity profile. Control of the electric motor
2804 may be open
loop or closed loop. Motor 2804 may be a liner motor, or a rotary motor
combined with
gearing, a linkage, cam, lead screw, or other mechanical element to drive the
plunger 2802.
[00161] Figures 29 a-c show an example device 2900 according to some
embodiments,
wherein controlled jet velocity is provided by a dampening mechanism
comprising an
elastomeric chamber 2902. This occurs in two steps. First, the plunger 2904 is
depressed to
fill the elastomeric chamber 2902, as shown in Figure 29b. Second the fluid
path to the
channel 2906 is opened, now spring force stored in the stretched elastomeric
chamber 2902
forces the fluid out of the channel 2906 as shown in Figure 29c.
[00162] The flow resistance of the fluid path out of the elastomeric chamber
2902 is
matched to the stiffness of the elastomeric chamber 2902 to provide a
controlled jet velocity
profile. As the elastomeric chamber 2902 relaxes, the pressure on the fluid
decreases, so
this provides an initial high velocity followed by a decrease in jet velocity.
- 27 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[00163] Figures 30 a-c show an example device 3000 according to some
embodiments,
wherein a carpule 3002 is depressed to fill the elastomeric chamber 3004 and
the fluid path
to channel 3006 is opened with a single motion. In this embodiment, a needle
3008 is
partially embedded in a septum 3010 to seal the end of the needle 3008, as
shown in Figure
.. 30a. First, as the plunger 3016 moves, the diaphragm 3012 is pierced. As
the plunger
3016 continues to move as shown in Figure 30b, the elastomeric chamber 3004 is
loaded
with fluid. The spring 3014 prevents travel of the carpule 3003 until the
plunger 3016 is
sufficiently depressed. Third, the plunger 3016 travel ends, the spring 3014
is compressed,
and the septum 3010 is pierced by needle 3008 as shown in Figure 30c. Fourth,
the
elastomeric chamber 3004 forces fluid out through the channel 3006. As the
elastic
elastomeric chamber 3004, pressure drops, providing a decreasing velocity
profile. Chamber
geometry can be varied to make a linear or non-linear decreasing velocity
profile.
[00164] Figure 31 shows an example device 3100 according to some embodiments,
wherein a large spring 3102 with a limited initial travel is used to break
static friction in the
piston 3106 and a second spring 3104 provides the force to fully dispense the
drug. Large
spring 3102 is a higher force spring than second spring 3104. The flow path
out of the
channel 3108 is long enough that the high velocity travel from the large
spring 3102 does not
cause fluid to leave the channel 3108.
[00165] Figure 32 shows an example device 3200 according to some embodiments,
wherein the flow rate of the jet is controlled by a flow restriction device
3202 between a
carpule 3204 and a channel 3206. The flow restriction device 3202 can be long
and gradual
to keep a laminar flow profile. This will prevent excessive shear on the
delivered drug (e.g.
protecting the viability of vaccines). The flow restriction device 3202 could
also be more
compact but producing a turbulent flow. This would make a more compact device
suitable for
delivering robust therapeutic agents. The flow restriction device 3202 could
also be replaced
by an active element like a constant velocity flow control valve, a pressure
relief valve, or a
pressure control valve.
[00166] Figure 33 a-c show an example device 3300 according to some
embodiments,
wherein the plunger 3302 is driven by a spring 3304, but piston velocity is
controlled by
bellows 3306 filled with air. As the piston 3302 travels up, the bellows 3306
are
- 28 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
compressed, and air is forced through a flow restriction 3308 (e.g. simple
orifice plate, small
drilled hole, pressure control valve, flow rate control valve). The rate that
the bellows 3306
can deform is controlled by the rate of air flow through the flow restriction
3308. This could
be accomplished by an arrangement where air is contained in a diaphragm 3310,
rolling
diaphragm or a piston as shown in Figures 33b and 33c. It may also be
accomplished in the
same configuration shown in Figure 33a but with a diaphragm, rolling
diaphragm, or piston.
[00167] Air may vent externally to the device, or it may vent into a secondary
chamber to
avoid the need for an external vent.
[00168] A prototype device including a cannula and dampening mechanism has
been
tested to demonstrate targeted delivery of the fluid bolus. The testing
comprised inserting the
cannula into the upper nares of a patient and ejecting a laminar flow of fluid
through the
cannula. In the testing, technicium 99 was used as a tracer fluid. A scan of
the patient
performed following the injection of the laminar flow of fluid show that the
fluid is deposited at
the olfactory region of the patient 3600, as shown in Figure 36. The presence
of the
technicium 99 appears as a light region on the scan shown in Figure 36.
[00169] The foregoing discussion provides many example embodiments of the
inventive
subject matter. Although each embodiment represents a single combination of
inventive
elements, the inventive subject matter is considered to include all possible
combinations of
the disclosed elements. Thus if one embodiment comprises elements A, B, and C,
and a
.. second embodiment comprises elements B and D, then the inventive subject
matter is also
considered to include other remaining combinations of A, B, C, or D, even if
not explicitly
disclosed.
[00170] The embodiments of the devices, systems and methods described herein
may be
implemented in a combination of both hardware and software. These embodiments
may be
implemented on programmable computers, each computer including at least one
processor,
a data storage system (including volatile memory or non-volatile memory or
other data
storage elements or a combination thereof), and at least one communication
interface.
- 29 -
CA 03096426 2020-10-07
WO 2019/195944
PCT/CA2019/050455
[00171] Program code is applied to input data to perform the functions
described herein
and to generate output information. The output information is applied to one
or more output
devices. In some embodiments, the communication interface may be a
network
communication interface. In embodiments in which elements may be combined, the
communication interface may be a software communication interface, such as
those for
inter-process communication. In still other embodiments, there may be a
combination of
communication interfaces implemented as hardware, software, and combination
thereof.
[00172] Throughout the foregoing discussion, numerous references will be made
regarding
servers, services, interfaces, portals, platforms, or other systems formed
from computing
devices. It should be appreciated that the use of such terms is deemed to
represent one or
more computing devices having at least one processor configured to execute
software
instructions stored on a computer readable tangible, non-transitory medium.
For example, a
server can include one or more computers operating as a web server, database
server, or
other type of computer server in a manner to fulfill described roles,
responsibilities, or
.. functions.
[00173] The technical solution of embodiments may be in the form of a software
product.
The software product may be stored in a non-volatile or non-transitory storage
medium,
which can be a compact disk read-only memory (CD-ROM), a USB flash disk, or a
removable hard disk. The software product includes a number of instructions
that enable a
computer device (personal computer, server, or network device) to execute the
methods
provided by the embodiments.
[00174] The embodiments described herein are implemented by physical computer
hardware, including computing devices, servers, receivers, transmitters,
processors,
memory, displays, and networks. The embodiments described herein provide
useful
.. physical machines and particularly configured computer hardware
arrangements.
[00175] Although the embodiments have been described in detail, it should be
understood
that various changes, substitutions and alterations can be made herein.
- 30 -
CA 03096426 2020-10-07
WO 2019/195944 PCT/CA2019/050455
[00176] Moreover, the scope of the present application is not intended to be
limited to the
particular embodiments of the process, machine, manufacture, composition of
matter,
means, methods and steps described in the specification.
[00177] As can be understood, the examples described above and illustrated are
intended
to be exemplary only.
- 31 -
